JNJ•benzinga•
Johnson & Johnson's TREMFYA Reduces Joint Damage And Improves Psoriatic Arthritis Symptoms In Phase 3b APEX Study, With Over 40% Achieving ACR50 And Majority Showing No Radiographic Progression At 24 Weeks
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 11, 2025 by benzinga